Related Experiment Video
Updated: Feb 15, 2026

Preparation of Exosomes for siRNA Delivery to Cancer Cells
Published on: December 5, 2018
VEGF siRNA Delivery by a Cancer-Specific Cell-Penetrating Peptide
Young Woong Lee1, Young Eun Hwang1, Ju Young Lee2
1Department of Biological Sciences, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Republic of Korea.
Abstract:
RNA interference provides an effective tool for developing antitumor therapies. Cell-penetrating peptides (CPPs) are delivery vectors widely used to efficiently transport small-interfering RNA (siRNA) to intracellular targets. In this study, we investigated the efficacy of the cancer-specific CPP carrier BR2 to specifically transport siRNA to cancer-target cells. Our results showed that BR2 formed a complex with anti-vascular endothelial growth factor siRNA (siVEGF) that exhibited the appropriate size and surface charge for in vivo treatment. Additionally, the BR2-VEGF siRNA complex exhibited significant serum stability and high levels of gene-silencing effects in vitro. Moreover, the transfection efficiency of the complex into a cancer cell line was higher than that observed in non-cancer cell lines, resulting in downregulated intracellular VEGF levels in HeLa cells and comprehensively improved antitumor efficacy in the absence of significant toxicity. These results indicated that BR2 has significant potential for the safe, efficient, and specific delivery of siRNA for diverse applications.
Insights
The novel BR2 peptide efficiently delivers anti-angiogenic siRNA to cancer cells, enhancing antitumor effects. This targeted delivery system shows promise for safe and effective cancer therapy development.
Area of Science:
- Biotechnology
- Molecular Biology
- Cancer Research
Background:
- RNA interference (RNAi) is a key strategy for developing antitumor therapies.
- Cell-penetrating peptides (CPPs) are crucial for intracellular delivery of small-interfering RNA (siRNA).
Purpose of the Study:
- To evaluate the cancer-specific CPP carrier BR2 for targeted siRNA delivery.
- To assess the efficacy of BR2-siRNA complexes in vitro and in vivo for cancer treatment.
Main Methods:
- BR2 peptide was complexed with anti-vascular endothelial growth factor siRNA (siVEGF).
- Complex characteristics (size, charge, serum stability) were analyzed.
- Gene silencing, transfection efficiency in cancer vs. non-cancer cells, and antitumor efficacy were evaluated in vitro and in vivo.
Main Results:
- BR2-siVEGF complexes demonstrated suitable properties for in vivo application.
- Significant serum stability and potent gene-silencing effects were observed in vitro.
- Higher transfection efficiency in cancer cells led to reduced VEGF levels and improved antitumor efficacy with minimal toxicity.
Conclusions:
- BR2 is a promising carrier for safe, efficient, and specific siRNA delivery in cancer therapy.
- The BR2-siVEGF complex shows potential for diverse therapeutic applications.
Related Concept Videos
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
Peptide Bonds
Cell Specific Gene Expression
Cell Specific Gene Expression
Small interfering RNAs (siRNA)
Cancer Cell Migration through Invadopodia

